tradingkey.logo

Bluejay Diagnostics Inc

BJDX
查看詳細走勢圖
0.706USD
-0.039-5.27%
收盤 12/24, 13:00美東報價延遲15分鐘
1.16M總市值
虧損本益比TTM

Bluejay Diagnostics Inc

0.706
-0.039-5.27%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-5.27%

5天

-20.31%

1月

-48.83%

6月

-55.86%

今年開始到現在

-85.50%

1年

-81.42%

查看詳細走勢圖

TradingKey Bluejay Diagnostics Inc股票評分

單位: USD 更新時間: 2025-12-24

操作建議

Bluejay Diagnostics Inc當前公司基本面數據相對非常健康,增長潛力較大。當前估值合理,在生物技術與醫療研究行業排名244/404位。機構持股佔比非常高,中期看,股價處於下降通道。近一個月,市場表現非常差,但基本面評分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Bluejay Diagnostics Inc評分

相關信息

行業排名
244 / 404
全市場排名
518 / 4562
所屬行業
生物技術與醫療研究

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 0 分析師
--
評級
--
目標均價
--
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Bluejay Diagnostics Inc亮點

亮點風險
Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes in critical care settings. It develops rapid tests using whole blood on its Symphony technology platform (Symphony), which consists of an analyzer and single-use protein detection cartridges that have the function of automatic stepwise feeding of reagent. The Symphony device is designed to produce laboratory-quality results in 20 minutes in critical care settings, including Intensive Care Units (ICUs) and Emergency Rooms (ERs). Its product candidate, the Symphony IL-6 test, is an immunoassay for the measurement of interleukin-6 (IL-6) to be used for the monitoring of disease progression in critical care settings. It is focused on pursuing the Symphony IL-6 test in the context of sepsis. IL-6 is a clinically established inflammatory biomarker, and is considered a 'first-responder', for the assessment of severity of infection and inflammation across many disease indications, including sepsis.
利潤高增長
公司淨利潤處於行業前列,最新年度總收入0.00美元
估值合理
公司最新PE估值-0.01,處於3年歷史合理位
詹姆斯·西蒙斯持倉
明星投資者詹姆斯·西蒙斯持倉,最新持倉0.00股

Bluejay Diagnostics Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Bluejay Diagnostics Inc簡介

Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes in critical care settings. It develops rapid tests using whole blood on its Symphony technology platform (Symphony), which consists of an analyzer and single-use protein detection cartridges that have the function of automatic stepwise feeding of reagent. The Symphony device is designed to produce laboratory-quality results in 20 minutes in critical care settings, including Intensive Care Units (ICUs) and Emergency Rooms (ERs). Its product candidate, the Symphony IL-6 test, is an immunoassay for the measurement of interleukin-6 (IL-6) to be used for the monitoring of disease progression in critical care settings. It is focused on pursuing the Symphony IL-6 test in the context of sepsis. IL-6 is a clinically established inflammatory biomarker, and is considered a 'first-responder', for the assessment of severity of infection and inflammation across many disease indications, including sepsis.
公司代碼BJDX
公司Bluejay Diagnostics Inc
CEODey (Neil)
網址https://bluejaydx.com/

常見問題

Bluejay Diagnostics Inc(BJDX)的當前股價是多少?

Bluejay Diagnostics Inc(BJDX)的當前股價是 0.706。

Bluejay Diagnostics Inc 的股票代碼是什麼?

Bluejay Diagnostics Inc的股票代碼是BJDX。

Bluejay Diagnostics Inc股票的52週最高點是多少?

Bluejay Diagnostics Inc股票的52週最高點是10.200。

Bluejay Diagnostics Inc股票的52週最低點是多少?

Bluejay Diagnostics Inc股票的52週最低點是0.712。

Bluejay Diagnostics Inc的市值是多少?

Bluejay Diagnostics Inc的市值是1.16M。

Bluejay Diagnostics Inc的淨利潤是多少?

Bluejay Diagnostics Inc的淨利潤為-34.16M。

現在Bluejay Diagnostics Inc(BJDX)的股票是買入、持有還是賣出?

根據分析師評級,Bluejay Diagnostics Inc(BJDX)的總體評級為--,目標價格為--。

Bluejay Diagnostics Inc(BJDX)股票的每股收益(EPS TTM)是多少

Bluejay Diagnostics Inc(BJDX)股票的每股收益(EPS TTM)是-99.673。
KeyAI